Amgen updates 2024 guidance with revenue and EPS ranges including consensus

mohd izzuan Amgen has provided updated 2024 guidance with its revenue and non-GAAP EPS guidance ranges both including the consensus estimate. The biotech sees full-year revenue of $33B to $33.8B.

Consensus is $33.2B. Non-GAAP EPS is seen at $19.



20 to $20. Consensus is $19.51.

.